Group One Trading LLC bought a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 90,331 shares of the exchange traded fund’s stock, valued at approximately $11,538,000.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Financial Life Planners purchased a new stake in SPDR S&P Biotech ETF in the first quarter valued at $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of SPDR S&P Biotech ETF during the 4th quarter valued at about $27,000. Intesa Sanpaolo Wealth Management purchased a new position in shares of SPDR S&P Biotech ETF during the 4th quarter valued at about $30,000. SHP Wealth Management acquired a new position in shares of SPDR S&P Biotech ETF in the 4th quarter valued at about $31,000. Finally, Legacy Wealth Managment LLC ID acquired a new position in shares of SPDR S&P Biotech ETF in the 4th quarter valued at about $32,000.
SPDR S&P Biotech ETF Stock Down 1.5%
Shares of XBI opened at $152.11 on Thursday. SPDR S&P Biotech ETF has a 52 week low of $84.39 and a 52 week high of $165.71. The company has a market capitalization of $10.21 billion, a price-to-earnings ratio of 11.47 and a beta of 0.82. The stock’s 50-day moving average price is $143.49 and its 200-day moving average price is $133.10.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Read More
- Five stocks we like better than SPDR S&P Biotech ETF
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
